Cost-effectiveness of human papillomavirus vaccination in Germany

BMC Cost Effectiveness and Resource Allocation
(Accessed 9 September 2017)

Cost-effectiveness of human papillomavirus vaccination in Germany
Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.
Oliver Damm, Johannes Horn, Rafael T. Mikolajczyk, Mirjam E. E. Kretzschmar, Andreas M. Kaufmann, Yvonne Deleré, Bernhard Ultsch, Ole Wichmann, Alexander Krämer and Wolfgang Greiner
Published on: 4 September 2017